23andMe Holding Co. (ME) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
23andMe Reports FY2022 Third Quarter Financial Results
February 10, 2022 4:04 PM ESTThird quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives
SUNNYVALE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, today reported its financial results for the third quarter (Q3) of its fiscal year 2022 (FY2022), which ended December 31, 2021. 23andMe is the only company with multiple FDA authorizations for... More
